| Identification | Back Directory | [Name]
2-Butenamide, N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinolinyl]-4-(dimethylamino)-, (2E)- | [CAS]
1351941-69-9 | [Synonyms]
sacibertinib 2-Butenamide, N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinolinyl]-4-(dimethylamino)-, (2E)- | [Molecular Formula]
C32H31ClN6O4 | [MOL File]
1351941-69-9.mol | [Molecular Weight]
599.08 |
| Hazard Information | Back Directory | [Uses]
Sacibertinib is a tyrosine kinase (Trk) inhibitor with EC50 value of 110 nM and 244 nM for EGFR-TK phosphorylation and HER2, respectively. Antineoplastic activity[1]. | [IC 50]
EGFR-TK phosphorylation: 110 nM (EC50); HER2: 244 nM (EC50) | [References]
[1] Hesheng Zhang, et al. Cyanoquinoline derivatives. CA2802130A1 (Example 138) [2] International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 36, No. 2, 2022. |
|
|